Merdury Biopharmaceutical Corporation

As of June 30, 2026, Merdury Biopharmaceutical Corporation carries a market capitalization of 2.58B, placing it among publicly traded companies globally. Its enterprise value stands at 2.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Merdury Biopharmaceutical Corporation has 427.65M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Merdury Biopharmaceutical Corporation maintains a current ratio of 7.76, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Merdury Biopharmaceutical Corporation's stock has gained approximately 4.79% over the past 52 weeks. The 50-day moving average sits at 5.98, while the 200-day moving average is 7.11.

As of June 30, 2026, Merdury Biopharmaceutical Corporation holds 136.49M in cash and equivalents against 42.80M in total debt, resulting in a net debt position of -41.33M. Total book value stands at 200.77M, with working capital of 132.39M providing operational flexibility.

Merdury Biopharmaceutical Corporation's most recent stock split took place on April 26, 2023 with a 157:158 split ratio.